# Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

> **NCT00634088** · PHASE1 · TERMINATED · sponsor: **R-Pharm** · enrollment: 13 (actual)

## Conditions studied

- Locally Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg
- **DRUG:** Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg
- **DRUG:** Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg
- **DRUG:** Ixabepilone + Lapatinib + Capecitabine

## Key facts

- **NCT ID:** NCT00634088
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2016-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00634088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00634088, "Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00634088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*